<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01128556</url>
  </required_header>
  <id_info>
    <org_study_id>MAC-01-10</org_study_id>
    <nct_id>NCT01128556</nct_id>
  </id_info>
  <brief_title>The Evaluation of Bepreve on the Measurement of Wheal and Flare Response From Histamine Skin Prick Testing</brief_title>
  <official_title>The Evaluation of the Effect of Bepreve, a Topical Ocular Antihistamine, on the Measurement of Wheal and Flare Response From Histamine Skin Prick Testing</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>North Texas Institute for Clinical Trials</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>North Texas Institute for Clinical Trials</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the effect of BEPREVE compared to a REFRESH Tears Lubricant eye drop on the&#xD;
      measurement of the wheal and flare from histamine skin prick testing. This is an open label,&#xD;
      two-week, post-marketing study conducted on histamine responsive patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>measurement of Wheal and Flare response from histamine skin-prick testing</measure>
    <time_frame>7 days</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Histamine Responsive Allergy Patients</condition>
  <arm_group>
    <arm_group_label>Bepreve</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>topical ocular treatment as indicated</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bepreve</intervention_name>
    <description>Bepreve (bepotastine besilate ophthalmic solution 1.5%) one drop in each eye twice daily</description>
    <arm_group_label>Bepreve</arm_group_label>
    <other_name>bepotastine besilate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Refresh Tears</intervention_name>
    <description>Refresh Tears one drop to each eye twice daily for 7 days after the conclusion of Bepreve treatment</description>
    <arm_group_label>Bepreve</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy male and female subjects, 18 to 65 years of age&#xD;
&#xD;
          -  Patients must demonstrate a positive reaction to a Histamine skin-prick test.&#xD;
             Manifested by a histamine-induced wheal of &gt;3mm in diameter over the normal saline&#xD;
             control after 15 minutes of elapsed time&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Significant signs and symptoms of currently active allergic disease (SAR, perennial&#xD;
             allergic rhinitis, episodic allergic rhinitis)&#xD;
&#xD;
          -  Upper respiratory tract infection, sinusitis, asthma or flu-like symptoms within 2&#xD;
             weeks prior to visit 1&#xD;
&#xD;
          -  Subjects who have dermatographism or other skin conditions which might interfere with&#xD;
             the interpretation of the skin test results&#xD;
&#xD;
          -  Subjects who are receiving escalating doses of immunotherapy, oral immunotherapy or&#xD;
             short course (rush) immunotherapy&#xD;
&#xD;
          -  Known hypersensitivity to the investigational product or to drugs with similar&#xD;
             chemical properties&#xD;
&#xD;
          -  Pregnancy and/or breast feeding&#xD;
&#xD;
          -  Use of antihistamines, NSAIDS, steroids, or other drugs which may affect the&#xD;
             skin-response&#xD;
&#xD;
          -  Use of any medications or agents that are not specified above that may confound the&#xD;
             interpretation of the results&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bob Q Lanier, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>North Texas Institute for Clinical Trials</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>North Texas Institute for Clinical Trials</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2010</verification_date>
  <study_first_submitted>May 21, 2010</study_first_submitted>
  <study_first_submitted_qc>May 21, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 24, 2010</study_first_posted>
  <last_update_submitted>July 7, 2010</last_update_submitted>
  <last_update_submitted_qc>July 7, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 8, 2010</last_update_posted>
  <responsible_party>
    <name_title>Bob Q. Lanier, M.D.</name_title>
    <organization>North Texas Institute for Clinical Trials</organization>
  </responsible_party>
  <keyword>allergic conjunctivitis</keyword>
  <keyword>histamine skin testing</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bepotastine besilate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

